BridgeBio to present real-world study comparing acoramidis with Pfizer’s tafamidis at HFSA 2026

BBIO•2026-10-06

BridgeBio said it will present clinical and real-world data on acoramidis for ATTR-CM at the HFSA Annual Scientific Meeting on Oct. 9-12, 2026, including an EHR-based comparison with Pfizer’s tafamidis.

1. Planned data presentations

BridgeBio said presentations will cover evidence on death risk and cardiovascular hospitalizations, as well as functional capacity, quality of life and kidney-related signals after treatment initiation. The company also plans to present comparative effectiveness data on acoramidis and tafamidis using electronic health records.

BridgeBio to present real-world study comparing acoramidis with Pfizer’s tafamidis at HFSA 2026

1. Planned data presentations

Related News

Honda reportedly delays next-generation CR-V hybrid production several months in US, Canada

Victoria’s Secret Chief Legal & Compliance Officer Melinda McAfee disposes of $410,769 in common shares

United Therapeutics chairperson, CEO Martine Rothblatt disposes of shares worth $4.91 million

C.H. Robinson Edge Report flags tightening trucking capacity as diesel prices hit records

S&P 500, Nasdaq reach record closing highs as focus pivots to earnings